Search clinical trials for: AL3810

Total 54 results

Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Unknown

Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810

Advanced Solid Tumor | Advanced/Metastatic Colorectal Cancer

China
Advenchen Laboratories, LLC

Available

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Gynecologic Cancer | Sarcoma,Soft Tissue
Haihe Biopharma Co., Ltd.

Unknown

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Extensive-stage Small Cell Lung Cancer

China
Shanghai Zhongshan Hospital

Withdrawn

Adjuvant Therapy With Anlotinib for HCC

Hepatocellular Carcinoma

China
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
First Affiliated Hospital Xi'an Jiaotong University
Tang-Du Hospital; Yan'an University Affiliated Hospital

Unknown

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Non-squamous NSCLC

China
Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Completed

Study of the AL3810 in the Treatment of Advanced Solid Tumor

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (ALTER0703)

Metastatic Colorectal Cancer

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing... and other collaborators

Unknown

Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy

Soft Tissue Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (ALTER0303)

Non-small Cell Lung Cancer

China
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
The First Affiliated Hospital of Xinxiang Medical...

Recruiting

Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (AP)

Lung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung Neoplasm

China
Huashan Hospital

Active, not recruiting

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

Malignant Glioma

China
Roncarolo, Maria Grazia, MD
National Cancer Institute (NCI)

Recruiting

Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders (T-allo10)

Hodgkin's Lymphoma | MDS (Myelodysplastic Syndrome) | ALL | Mixed Phenotype Acute Leukemia | AML - Acute Myeloid Leukemia | NHL - Non-Hodgkin's Lymphoma

United States
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Advenchen Laboratories, LLC

Active, not recruiting

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (APROMISS)

Leiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue Sarcoma

United States, United Kingdom, Spain, China, Italy
Advenchen Laboratories, LLC

Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (AL3818)

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
Ruijin Hospital

Recruiting

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Soft Tissue Sarcoma | Radiotherapy | Anlotinib | High Risk of Recurrence

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

Stage III Non-small-cell Lung Cancer

China
Shi Yuankai

Recruiting

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Head and Neck Squamous Cell Carcinoma

China
Teresa Helsten, MD
Clovis Oncology, Inc.

Withdrawn

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Advanced Cancer

United States
Sun Yat-sen University

Not yet recruiting

Peramprizumab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Porteus, Matthew, MD
California Institute for Regenerative Medicine (CIRM)

Recruiting

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

Hematologic Diseases

United States
Peking University People's Hospital

Unknown

Anlotinib and Irinotecan for Ewing Sarcoma

Ewing's Tumor Metastatic

China
Sarcoma Oncology Research Center, LLC
Advenchen Laboratories, LLC

Active, not recruiting

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Non Small Cell Lung Cancer | Solid Tumor, Adult

United States
GlaxoSmithKline

Terminated

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

HIV Infection

United States, Germany, Belgium, Canada, Denmark
Zhejiang Cancer Hospital

Recruiting

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Breast Neoplasm Female

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

Small Cell Lung Carcinoma

China
Institut de Recherches Internationales Servier

Completed

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Solid Tumors

Italy, France, Spain
Henan Cancer Hospital

Recruiting

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Breast Cancer

China
University of Bath

Completed

Exercise Interventions for Improving Health in Breast Cancer Survivors

Breast Cancer Female

United Kingdom
Clovis Oncology, Inc.

Terminated

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ER

United States
Tianjin Medical University Second Hospital

Not yet recruiting

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Urogenital Neoplasms | Urothelial Carcinoma | Antineoplastic Agents | Gemcitabine | Cisplatin | Anlotinib | Carboplatin

China
Sichuan Provincial People's Hospital

Recruiting

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (NeoATCT)

Triple-negative Breast Cancer

China
Eisai Co., Ltd.

Completed

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Functional Dyspepsia

Japan
Eisai Co., Ltd.

Completed

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

Refractory Reflux Esophagitis

Japan
Eisai Co., Ltd.

Completed

A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Eisai Co., Ltd.

Completed

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Healthy

Japan
Eisai Co., Ltd.

Completed

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Gastroesophageal Reflux Disease

Japan
Zhejiang Cancer Hospital

Unknown

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Eisai Inc.

Completed

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Healthy

United States
Yonsei University

Completed

Comparison of Conventional Lightwand Intubation Versus Video-laryngoscope Guided Lightwand Intubation in Simulated Cervical Spine-immobilized Patients

General Anesthesia

Korea, Republic of
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
Eisai Co., Ltd.

Completed

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Japan
Eisai Co., Ltd.

Completed

Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin

Japan
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy

3

Subscribe